In today’s briefing:
- Boryung Pharmaceutical (003850 KS): Focus on Prescription Drugs for Stability and Accelerated Growth
Boryung Pharmaceutical (003850 KS): Focus on Prescription Drugs for Stability and Accelerated Growth
- Boryung Pharmaceutical (003850 KS) aims to achieve a revenue CAGR of 10.9% during 2022–2026 (from 7.8% in 2017–2021) through a chronic disease-focused prescription drug portfolio.
- While hypertension and dyslipidemia drugs remain its cash cow, Boryung has identified oncology and CNS as its new growth engine to achieve KRW1 trillion revenue in 2026.
- Driven by a 28% y/y growth in prescription drug revenue, Boryung has reported record high quarterly sales and operating profit in Q1 2022. The company is continuously launching new drugs.
Related tickers: Boryung Pharmaceutical (003850.KS)
Before it’s here, it’s on Smartkarma
